The calcium-sensing receptor (CaR) is a G-protein-coupled receptor that plays a key role in extracellular calcium ion homeostasis. We have engineered 11 CaR mutants that have been described in the disorders familial benign hypercalcemia ( 
Introduction
The cell surface calcium-sensing receptor (CaR) 1 is expressed in the parathyroid glands and kidneys where it allows regulation of parathyroid hormone (PTH) secretion and renal tubular calcium reabsorption appropriate to the prevailing extracellular calcium concentration [Ca ] o (1) (2) (3) (4) (5) . The CaR is a member of the superfamily of G-protein-coupled receptors (GPCR) and has a large, 612 amino acid extracellular domain that is thought to bind calcium or other agonists such as magnesium, gadolinium, and neomycin (2-7). Ligand binding results in G-protein dependent stimulation of phospholipase C activity causing accumulation of inositol 1,4,5-trisphosphate (IP 3 ) (2, 8) and rapid release of calcium ions [Ca ] i from intracellular stores followed by an influx of extracellular calcium (9) (10) (11) . These intracellular events are thought to mediate a decrease in the rate of PTH secretion from the parathyroid cell and a reduction in renal tubular calcium reabsorption (1) (2) (3) (4) . Thus, the CaR plays a key role in the regulation of extracellular calcium homeostasis. Structurally the CaR is an unusual member of the GPCR superfamily, in that it has the 7 hydrophobic transmembrane domains typical of such receptors but has little sequence homology to most other family members (2) (3) (4) (5) . Although members of the metabotropic glutamate receptor subfamily (mGluRs) do share limited homology to the CaR, this structural similarity is weak with only 30% amino acid identity between the CaR and the most homologous member, mGluR1 (2) (3) (4) (5) 12) . Thus, little is known about the structure-function relationships of this important receptor.
Mutations in GPCRs may cause either a loss of receptor function, as found in the type 2 vasopressin and the adrenocorticotropin receptors in the disorders of X-linked nephrogenic diabetes insipidus and familial glucocorticoid deficiency, respectively (13, 14) , or a gain of receptor function, as found in the thyrotropin and luteinizing hormone receptors in the disorders of toxic thyroid adenoma and familial male precocious puberty, respectively (15, 16) . Similar mutations in the CaR have been reported in association with two hypercalcaemic disorders, familial benign (hypocalciuric) hypercalcemia (FBH) and neonatal severe hyperparathyroidism (NSHPT) (17) (18) (19) (20) (21) (22) , and also in association with an autosomal dominant form of hypocalcemia (ADH) (23) (24) (25) . Functional expression of five missense mutations associated with FBH in Xenopus laevis oocytes has shown that they cause a reduction in the [Ca ] o -activated chloride influx that results from CaR-mediated activation of PLC compared to the wild type receptor, consistent with the predicted loss or reduction of CaR function (17, 20) . Similarly, expression of a mutation found in a family with ADH in the Xenopus system confirmed an increase in basal and stimulated intracellular IP 3 accumulation, consistent with a gain of receptor function, although no difference in [Ca ] oactivated chloride currents could be demonstrated (23) . How-ever, there are important differences between the CaR mediated responses observed in X. laevis oocytes compared to mammalian cells, as agonist dependent IP 3 accumulation is inhibited by pertussis toxin in the Xenopus system, whereas in dispersed mammalian parathyroid cells this response is pertussis toxin insensitive, suggesting differences in the specificity of the G protein coupling (1, 2) . In order to gain further insight into the structure-function relationships of the CaR, we have expressed a further 11 mutations in the CaR that we have previously documented to be associated with FBH, NSHPT, or ADH (19, 25, 26) 
Methods
Site-directed mutagenesis. The wild type human CaR cDNA (HuPCaR4.0) (3) was ligated into pBluescript SK( Ϫ ) (pBSK) (Stratagene, La Jolla, CA), and five unique silent restriction enzyme sites were introduced using oligonucleotides to give six cassettes, which ranged between 0.5 and 1kb in length, encompassing the entire CaR coding sequence. These cassettes were used to make single stranded DNA templates from pBSK( Ϫ ) using helper phage for in vitro replication, and mutagenic oligonucleotides corresponding to the previously reported mutations (19, 25, 26) were annealed to these templates, ligated and used to make double stranded mutant DNA with T4 DNA polymerase (New England Biolabs, Beverly, MA) (27) . The synthesized dsDNA mutant cassettes were used to transform DH5 ␣ cells (GIBCO-BRL, Gaithersburg, MD). Colonies containing the mutant construct were then screened for by PCR using pBSK( Ϫ ) vector primers followed by restriction enzyme digestion, employing enzymes corresponding to the desired mutation (19, 25, 26) . For mutations that did not alter a restriction site, a second silent base change was made in the mutagenic oligonucleotide to enable such screening. Mutant clones were sequenced in both directions using fluorochrome-labeled dideoxy terminators (Applied Biosystems, Foster City, CA). The mutated cassettes were then excised from the pBSK( Ϫ ) and ligated back into the wild type CaR cDNA in a mammalian expression vector with a CMV promoter and bovine growth hormone 3 Ј untranslated region (pcDNA3; Invitrogen, San Diego, CA).
Cell culture and transfection. Human embryonic kidney cells (HEK 293, ATCC No. CRL-1573) were grown to 80-90% confluence on 13.5 ϫ 20.1 mm glass cover slips in Dulbecco's modified Eagle's medium (GIBCO-BRL) supplemented with 10% heat-inactivated fetal calf serum (Hyclone, Logan, UT). Transfection was performed using 2.5 g of wild type or mutant DNA per cover slip which was first dissolved in 125 l of serum-free medium (Opti-MEM; GIBCO-BRL) and then mixed with a suspension of 5% lipofectamine (GIBCO-BRL) in 250 l of serum free medium. After incubation for 30 min at 20 Њ C to allow DNA-liposome complexes to form, the cellcoated cover slip was immersed in a 1:5 dilution of this mixture with fresh serum-free medium and incubated at 37 Њ C for 5 h. This was followed by addition of an equal volume of serum-free medium supplemented with 20% fetal calf serum. Co-transfection of two clones was carried out in a similar manner except that only 0.5 g of each DNA were dissolved in the 125 l of serum-free medium before addition of the liposome solution. (11, 28) , and each mutant construct was studied on at least two occasions with separate transfections. Cover slips were loaded by incubation of transfected cells with 4 M of the acetoxymethyl ester of fura-2 (Molecular Probes, Eugene, OR) for 2 h at room temperature in 1 ml of a buffer containing 130 mM NaCl, 4 mM KCl, 0.5 mM CaCl 2 , 0.5 mM MgCl 2 , 20 mM Hepes, 1% dextrose, and 1% BSA (pH 7.4 at 37 Њ C), which was used for all further manipulations. After this the cover slips were washed for 20 min before insertion into a quartz cuvette fitted with a magnetic stir bar in a thermostatted platform maintained at 37 Њ C. A dual wavelength xenon light source was used with a pair of monochrometers centered at 340 and 380 nm to excite the fura-2, and the emitted signal, filtered at 510 Ϯ 40 nm was detected with a photon-counting photomultiplier tube (Photon Technology International, Princeton, NJ), as described (29) . To assess [Ca ] i increment occurred), to produce a "normalized" response (R n ). Thus, R n ϭ ␦ x ϩ␦ x Ϫ 1 ϩ␦ x Ϫ 2 . . ./ ␦ n and for example, for the response to 4.5 mM [Ca ] i response would be { ␦ 1 ϩ␦ 2 ϩ␦ 3 / ⌺␦ n }. The magnitude of the maximal response ( ⌺␦ n ) varied depending on the cell density and the level of fura-2 loading, but there was a consistent relationship between the responses of each mutant and that of the wild type examined on the same day. Moreover, this cumulative peak concentration-response curve was similar to that determined by combining several experiments where [Ca ] o was increased from 0.5 mM to a single higher level (e.g., 2.5 or 5.0 mM). Individual EC 50 s for each incremental, normalized concentration-response curve were plotted, and the mean EC 50 for several experiments was used for statistical comparisons.
HEK cell membrane preparation and Western analysis. Membrane fractions were isolated from confluent cultures of HEK-293 cells that had been transfected with 15 g of wild type or mutant CaR constructs 48 h previously. Cells were dislodged with 0.02% EDTA in PBS, pelleted, and resuspended in 300 l of homogenization buffer (50 mM Tris-HCl, pH7.4; 0.32 M sucrose; 1 mM EDTA; aprotinin 83 g/ml; leupeptin 30 g/ml; pefabloc 1 mg/ml; calpain inhibitor 50 g/ ml; bestatin 50 g/ml; pepstatin 5 g/ml) at 4ЊC. The cells were then homogenized with 15 strokes of a teflon pestle and nuclei and mitochondria sedimented at 18,800 g for 20 min, followed by 43,500 g for 20 min to pellet the membranes. Membrane pellets were solubilized in 1% Triton X-100 and 8 g of protein was separated by SDS-polyacrylamide gel electrophoresis on a linear gradient (4-12%). The proteins on the gel were electrotransferred to nitrocellulose membranes and after blocking with 5% milk, the blots were incubated with 1:3000 dilution of antiserum (4641) raised against a synthetic peptide corresponding to residues 215-237 of the CaR. The 4641 antiserum has been previously demonstrated to be CaR specific, with binding abolished by peptide pre-incubation, and to recognize identical bands in preparations of bovine parathyroid cell membranes as in CaR transfected HEK-293 cell membranes, with no immunostaining of untransfected HEK cells (30) . A goat anti-rabbit secondary antibody (Sigma Chemical Co., St. Louis, MO) was used which was conjugated to horseradish peroxidase enabling detection of the CaR protein by enhanced chemiluminescence (Amersham, Arlington Heights, IL).
Statistical analysis. ] o over which [Ca 2ϩ ] i responses were observed for the wild type (WT) receptor and for the various loss-and gain-of-function mutants (Fig. 2) . Preliminary experiments revealed that HEK cells transfected with WT CaR cDNA had a threshold for a re-sponse to [Ca 2ϩ ] o of between 1.5 and 2.0 mM, an EC 50 [Ca 2ϩ ] o of between 3.5 and 4.5 mM and a near maximal (95% or greater) response at 15 mM Ca (Fig. 1) . A Hill plot of these concentration-response curves gave a mean Hill coefficient of 3.1Ϯ0.1. The sigmoidal nature of this concentration-response curve ( Fig. 1) was consistent with that which we observed by combining several experiments in which a single concentration of [Ca 2ϩ ] o was added to each cover slip in this system, with the EC 50 [Ca 2ϩ ] o differing by less than 10% between the multiple increment compared to the single stimulus experiments. Similarly, the concentration-response curve was also consistent with that previously observed for the native receptor both in vivo and in vitro in parathyroid cells and in vitro in Xenopus laevis oocytes injected with cRNA encoding the CaR (1-5, 9-11). Although this "1 mM" incremental [Ca 2ϩ ] o "ladder" allowed easy differentiation of the WT response from that of inactivating CaR mutations, it was not sufficiently sensitive to allow good characterization of the response to levels of [Ca 2ϩ ] o ] o there is a discrete peak in the ratio of the emmited fluorescence counts (at 340 vs 380 nm excitation) reflecting concomitant changes in [Ca 2ϩ ] i (y-axis), the magnitude of which we have designated ␦ n . It can be seen from these data that the threshold for a [Ca 2ϩ ] o . response in cells expressing the WT receptor is around 2.5 mM compared to 3.5 mM for P55L. It can also be seen that the concentration-response curve of the mutant receptor is shifted rightwards compared to the WT CaR. The method of normalization of the fluorescence ratio is described in detail in ] o -regulated PTH release in parathyroid cells, and the EC 50 s of these mutations are all significantly different from that for the WT CaR (Table I ). in the range of 1.5-3 mM, which coincided with the apparent EC 50 ] o s ranging from 5.5 mM to 9.3 mM (Table  I ) with a rightward shift of the concentration-response curves to [Ca 2ϩ ] o as shown in Fig. 1 ] o . To examine the possible role of gene dosage effects in vitro, we co-transfected the mutation R227L, which was found as a heterozygous mutation in a child with a form of NSHPT (19) , with an equal amount of WT receptor cDNA. Thus, the HEK-293 cells were rendered "heterozygous" for this mutation, which created a large rightward shift in EC 50 [Ca 2ϩ ] o when transfected alone ("homozygous") ( Table  I ). The cells co-transfected with both WT and R227L DNA (0.5 g each) had an EC 50 [Ca 2ϩ ] o of 5.1 mM (Ϯ0.13), which differed significantly from both that for WT receptor DNA (0.5 g) alone [4.3 mM (Ϯ0.08)] and for R227L (0.5 g) alone [8.5 mM (Ϯ0.25)] (P Ͻ 0.01, Duncan test) (Fig. 3) .
Functional assessment of CaR mutations associated with autosomal dominant hypocalcemia. Using a 0.5 mM incremental [Ca 2ϩ ] o concentration regimen, the mean EC 50 of the WT receptor was 3.7 mM (Ϯ0.05). The mean EC 50 [Ca 2ϩ ] o s of three mutations (F128L, T151M, and E191K) associated with ADH were 2.2 mM (Ϯ0.05), 2.7 mM (Ϯ0.04), and 2.8 mM (Ϯ0.06) (all n ϭ 6), respectively. These EC 50 [Ca 2ϩ ] o s all demonstrate a significant (P Ͻ 0.01) leftward shift compared to WT using the same 0.5 mM incremental ladder (Fig. 4) . The maximal responses of each of these mutations were once again consistent when compared to WT controls assessed with the same incremental concentration ladder on the same day, such that the maximal responses were 94%, 130%, and 137% of the WT response for the mutants F128L, T151M, and E191K, respectively.
Western analysis of expressed wild type and mutant CaR proteins. Membrane fractions from the HEK-293 cells that had been transfected with either WT or the five mutant CaR clones P55L, N178D, R227L, R680C, and V817I showed three immunoreactive bands between 120 and 160 kD (Fig. 5 ), which were consistent with the observed size of the CaR in parathyroid cell membranes (30) and which were abolished by peptide preabsorption. The frameshift mutation P747fs, which predicts ] o that is right-shifted compared to that seen in cells transfected with WT alone (P Ͻ 0.01) and is also significantly different from that in cells transfected with only R227L DNA. Thus the presence of the mutant CaR causes a shift in the EC 50 [Ca 2ϩ ] o to the right despite the presence of the normal CaR.
a CaR truncated at codon 775 (19) showed a smaller band of about 80 kD (Fig. 5) consistent with a truncated protein. The quantity of the expressed WT CaR protein was comparable to that of the six mutant CaRs (P55L, N178D, R227L, R680C, P747fs, V817I) (Fig. 5) , thereby indicating that the abnormal functional responses of the mutant CaRs are not due to a lack of receptor expression on the cell membrane. However, as the 4641 antibody was raised against residues 215-237 of the CaR (30), we were unable to assess the expression of the 2 mutations, Y218S and P221S, which are predicted to interfere with the conformation of the antibody binding site.
Discussion
We have characterized the [Ca 2ϩ ] i responses of 11 CaR mutants (8 associated with loss of function and 3 associated with gain of function) (Fig. 2) expressed in human embryonic kidney cells to stepwise increases in [Ca 2ϩ ] o . Our results show that three different classes of inactivating CaR mutants may exist. First, two of the mutations (R680C and P747fs) associated with FBH and NSHPT gave no response to either calcium or gadolinium. The P747fs mutation predicts a CaR which lacks three transmembrane domains. It would, therefore, probably be unable to couple normally to the associated G protein(s), which is thought to occur via the third intracellular loop in the majority of GPCRs (17, 31, 32) although in the structurally homologous metabotropic glutamate receptor subfamily, the second intracellular loop appears to be particularly important in this regard (34) . Our finding that this receptor is expressed (Fig. 5 ) but is nonfunctional supports this hypothesis, although it is possible that that the abnormal receptor protein fails to reach the cell surface. The other nonfunctional mutation, R680C, results in a novel cysteine residue in the first extracellular loop. Many other GPCRs have a disulfide bridge between the first and second extracellular loops which has been shown to be important for maintenance of secondary structure (32, 33) . It is possible that the novel cysteine of this mutation forms an aberrant bridge with one of the other cysteines and that this disrupts the critical relationship of the transmembrane domains, thereby preventing signal transduction. Alternatively, such an abnormal disulfide bridge might destabilize the protein and/or reduce the expression of its glycosylated forms on the cell surface (Fig. 5) .
The second class of mutations are those that cause a rightward shift in the EC 50 [Ca 2ϩ ] o of the CaR (Fig. 1) . Four of these are in the extracellular domain of the receptor where they either predict structural change (i.e., loss of a "helix-breaking" proline, P55L and P221S) or net loss of positive charge (N178D and R227L). It is probable that these mutations alter the structure or charge distribution of the ligand-binding site(s) in such a way as to reduce the affinity of the receptor for cations. The remaining mutation of this class is the conservative V817I mutation which occurs within the hydrophobic sixth transmembrane domain of the CaR and produces a subtle shift in response (EC 50 [Ca 2ϩ ] o ϭ 5.5 mM). It seems possible that the additional methylene group of the isoleucine residue may stabilize this transmembrane domain and inhibit a putative conformational change necessary to activate the G protein(s). The third type of inactivating mutation that we have studied is the FBH mutation Y218S. This mutation produces a CaR with an attenuated and qualitatively different response to calcium ] o was increased from a base-line value of 0.5 mM in 0.5 mM increments to 4.0 mM, then a single concentration of 10 mM was applied. The X-axis shows the increasing [Ca 2ϩ ] o concentrations up to this 10 mM maximum, in distinction from the 20mM maximum used in other series of experiments ( Fig. 1 b and Fig. 3 ). Responses of [Ca 2ϩ ] i were measured and normalized for the maximal [Ca 2ϩ ] i response, as described in methods. The EC 50 for the WT receptor was significantly different from that of each of the three mutant CaRs, which were all significantly left-shifted (P Ͻ 0.01). Vertical bars through points represent SEMs. (30) . Cells transfected with the WT CaR cDNA can be seen to express three immunostainable bands between 120 and 160 kD. The cells transfected with the 4 loss of CaR function mutations, P55L, N178D, R227L, and V817I all demonstrate a similar quantity of immunoreactive receptor protein. The frameshift mutation, P747fs, which predicts a CaR lacking 3 transmembrane domains and the intracellular tail shows a smaller band of about 80 kD, whereas the mutation R680C has a reduced intensity of the 160-kD band compared to WT, suggesting reduced quantities of N-linked glycosylation or other post-translational modification of this mutant.
(EC 50 [Ca 2ϩ ] o Ͼ 50 mM) but has only a modest rightward shift in EC 50 (36) all support the idea that the CaR may have either different or overlapping ligand-binding sites for calcium and gadolinium.
As heterozygous CaR mutations are found in most subjects with FBH (17-22) and in some individuals with NSHPT (19), we co-transfected HEK cells with both WT and mutant (R227L) cDNAs to produce "heterozygosity" in vitro. The EC 50 [Ca 2ϩ ] o of these "heterozygous" cells was right-shifted and approximately intermediate between that observed for the wild type receptor and for R227L cDNA when transfected alone (Fig. 3) . Thus, the presence of the WT CaR is not able to "rescue" the EC 50 of cells expressing this mutant CaR. Additional studies are necessary to determine whether the mutant receptor exerts a true dominant-negative effect, for instance by interfering with WT receptors by dimerization, or simply reduces the effective concentration of WT receptor on the cell surface, as found in mice heterozygous for a disruption of the CaR gene, which manifest mild hypercalcemia (37) .
We have also demonstrated that three mutations associated with hypocalcemia appear to cause gain of receptor function by lowering the EC 50 [Ca 2ϩ ] o for [Ca 2ϩ ] o -elicited increase in [Ca 2ϩ ] i (Fig. 4) . This is consistent with the levels of IP 3 documented for another such mutation when expressed in the Xenopus system (23) . The left-shifted EC 50 [Ca 2ϩ ] o s of these mutations would explain their dominant nature in vivo, as PTH secretion is negatively regulated by CaR activation (1, 9) and it would be predicted, therefore, that inhibition of PTH secretion would occur at an inappropriately low concentration of [Ca 2ϩ ] o to produce a stable level of PTH secretion at a lower [Ca ϩ ] o . All of these mutations are within the extracellular domain of the receptor and two of them, F128L and T151M, predict a structural change, whereas the other, E191K, predicts the gain of a positive charge. It seems likely that these mutations alter the ligand-binding site(s) in such a way as to enhance the affinity of the receptor for [Ca 2ϩ ] o , producing CaR activation at lower than normal levels of [Ca 2ϩ ] o . Thus, we have demonstrated that these different CaR mutants may cause loss or gain of [Ca 2ϩ ] o -responsive CaR function which is correlated clinically with the disorders FBH and NSHPT, and ADH, respectively. Furthermore, these studies have also provided insights into the possible nature and specificity of the CaR's ligand-binding site(s) (35) , and of the predicted structure-function relationships (2-5) of this novel G-protein-coupled receptor.
